BioSyent Inc. · TSXV:RX
BioSyent — Q4 2022 Earnings Presentation
17 slides from BioSyent's earnings presentation, Mar 21, 2023
Slide 1: BioSyent Inc. Q4 / FY 2022 Results
BioSyent Inc. Q4 / FY 2022 Results MARCH 21, 2023 PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Sales, EBITDA and NIAT - Q4 2022
Sales, EBITDA and NIAT Quarter (Q4) ended December 31, 2022 8,000 Q4 2022 Sales: +26% +3% +13%* Canadian Pharma 7,000 -63% International Pharma -87% Legacy 6,000 +3% *+27% on Continuing Canadian 5,000 Pharma Brands (excluding brands discontinued in Jan 2022) CAD (000's) 4,000 50 Consecutive Profitab
Slide 4: Sales, EBITDA and NIAT - Full Year 2022
Sales, EBITDA and NIAT Full Year (FY) ended December 31, 2022 30,000 +28% -2% FY 2022 Sales: 25,000 +2%* Canadian Pharma +4% -58% International Pharma -18% Legacy 20,000 *+11% on Continuing Canadian CAD (000's) 15,000 Pharma Brands (excluding brands discontinued in Jan 2022) 10,000 +57% -15% -3% +66
Slide 5: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS Q4 2022 $1,199,516 $0.09 Q3 2022 $1,453,042 $0.12 $0.44 Q2 2022 $1,217,883 $0.10 Q1 2022 $1,587,904 $0.13 Q4 2021 $1,877,804 $0.15 Q3 2021 $1,721,320 $0.13 $0.49 Q2 2021 $1,018,074 $0.08 Q1 2021 $1,664,368 $0.13 5 | www.biosyent.com | TSXV: R
Slide 6: Q4 / FY 2022 Sales Summary
Q4 / FY 2022 Sales Summary Q4 ‘22 Q4 ‘22 vs. FY ‘22 FY ‘22 vs. Sales ($) Q4 ’21 (%) Sales ($) FY ’21 (%) Canadian Pharma ($) $7,289k +13% $26,522k +2% FeraMAX® (units) +12% +2% Continued growth from RepaGyn® (units) +31% +14% established brands FY 2022 Cathejell® (units) +3% +4% Tibella® (units) +41
Slide 7: Most recommended iron supplement in Canada
▪ Most recommended iron supplement in Canada - pharmacists and physicians - 7 consecutive years(1) ▪ Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recomme
Slide 8: A New Platform for FeraMAX Product Innovation
A New Platform for FeraMAX® Product Innovation ▪ FeraMAX® Pd platform introduced in October 2020 ▪ Patented delivery system based on Polydextrose Iron Complex (“PDIC”) ▪ Foundation for future product development ▪ FeraMAX® Pd Therapeutic 150 launched Nov 2020 ▪ FeraMAX® Pd Powder 15 launched Oct 202
Slide 9: Introducing FeraMAX Pd Maintenance 45
Introducing FeraMAX® Pd Maintenance 45 ▪ Developed by BioSyent ▪ BioSyent’s third product incorporating PDIC ▪ Unique Formulation containing: ▪ 45 mg elemental iron as PDIC ▪ 75 mg vitamin C ▪ 1,000 mcg vitamin B12 ▪ Designed to fill an unmet need: ▪ prevent iron deficiency ▪ maintain healthy iron l
Slide 10: 10 | www.biosyent.com | TSXV: RX
10 | www.biosyent.com | TSXV: RX
Slide 11: Growth Drivers
Growth Drivers Investments In: FeraMAX® Pd Platform – Life Cycle Strategy • Additional products in development Field Salesforce HRT agent for menopause therapy • Launched July 2020 First formulation combining acetaminophen + Marketing Resources ibuprofen for pain relief in Canada • Promotion initiat
Slide 12: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) 30,000 25% • Zero Debt 28,000 21% 28,696 • 2022 Cash from Operations 28,211 20% of $4.9M 26,000 17% • 2022 NCIB share buybacks: 15% 25,578 14% $3.4M 24,000 CAD (000's) RoE % 10% • Q4 2022 Dividend of $0.5M 22,000 • Dec 31/22 Working Capital of 20,000 5% $31.4M
Slide 13: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $28.7M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders • $0.04/share Dividend – Q4 2022 + Q1 2023 = $1.0 M • 424,
Slide 14: Normal Course Issuer Bid (NCIB)
Normal Course Issuer Bid (NCIB) Fully Diluted No. Shares Shares Period Repurchased Outstanding Dec 10, 2018 14,675,307 424,700 shares NCIB Purchases: Dec 10, 2018 – present (2,200,625) purchased in 2022 As of March 17, 2023 12,507,615 ▪NCIB renewed for 12 months Dec 2022 – Dec 2023 ▪15% reduction in
Slide 15: Stock Information
Stock Information As at March 17, 2023 Exchange & Trading Symbol 0% TSXV: RX March 17, 2023 Closing Stock Price (CAD) $7.25 52 Week Hi/Low: $10.00 / $6.24 Issued Common Shares: 12,339,161 Treasury – RSU Shares in Trust (241,300) Outstanding Common Shares: 12,097,861 Options Outstanding 164,295 RSUs
Slide 16: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 16 | www.biosyent.com | TSXV: RX
Slide 17: Thank You
THANK YOU 2476 Argentia Road, Suite 402 +1 905 206 0013 [email protected] www.biosyent.com Mississauga ON L5N 6M1 Canada 17 | www.biosyent.com | TSXV: RX